Cargando…

Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis

INTRODUCTION: Remission induction in antineutrophil cytoplasmic autoantibody (ANCA) vasculitis may be complicated by slow response to treatment and toxicity from glucocorticoids. We describe outcomes with a novel remission induction regimen combining rituximab with a short course of low-dose, oral c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cortazar, Frank B., Muhsin, Saif A., Pendergraft, William F., Wallace, Zachary S., Dunbar, Colleen, Laliberte, Karen, Niles, John L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5932132/ https://www.ncbi.nlm.nih.gov/pubmed/29725643 http://dx.doi.org/10.1016/j.ekir.2017.11.004

Ejemplares similares

Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series
por: Cortazar, Frank B., et al.
Publicado: (2017)

A Case of Rituximab Use as an Induction and Maintenance of Remission in ANCA-Associated Vasculitis
por: Awad, Neveen, et al.
Publicado: (2016)

Adding low dose cyclophosphamide to rituximab for remission-induction may prolong relapse-free survival in patients with ANCA vasculitis: A retrospective study
por: Ysermans, Renée, et al.
Publicado: (2022)

Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis
por: Smith, Rona M, et al.
Publicado: (2020)

Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: A randomised trial
por: Maritati, Federica, et al.
Publicado: (2017)

Boon and bane of remission induction with rituximab in ANCA-associated vasculitis: lessons learned from the RAVE-ITN follow-up study
por: Kronbichler, Andreas
Publicado: (2013)

Rituximab Induction and Maintenance in ANCA-Associated Vasculitis: State of the Art and Future Perspectives
por: Treppo, Elena, et al.
Publicado: (2021)

Low-Dose Intravenous Methylprednisolone in Remission Induction Therapy for ANCA-Associated Vasculitis
por: Floyd, Lauren, et al.
Publicado: (2023)

Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated Vasculitis: a multi-center retrospective cohort study
por: Chanouzas, Dimitrios, et al.
Publicado: (2019)

Personalized Medicine in ANCA-Associated Vasculitis ANCA Specificity as the Guide?
por: Wallace, Zachary S., et al.
Publicado: (2019)

The Role of Mycophenolate Mofetil for the Induction of Remission in ANCA-Associated Vasculitis: A Meta-Analysis
por: Xiong, Anji, et al.
Publicado: (2021)

B cell depletion by Rituximab severely reduces immunoglobulin levels in patients with ANCA-associated vasculitis previously treated with cyclophosphamide
por: Thiel, Jens, et al.
Publicado: (2011)

Induction treatment of previously undiagnosed ANCA-associated vasculitis in a renal transplant patient with Rituximab
por: Graham-Brown, M. P. M., et al.
Publicado: (2016)

Rituximab induction therapy for de novo ANCA associated vasculitis in pregnancy: a case report
por: Harris, Claire, et al.
Publicado: (2018)

PR3-ANCAs predict relapses in ANCA-associated vasculitis patients after rituximab
por: van Dam, Laura S, et al.
Publicado: (2020)

Cyclophosphamide induction dose and outcomes in ANCA-associated vasculitis with renal involvement: A comparative cohort study
por: Speer, Claudius, et al.
Publicado: (2021)

Treatment of Aggressive Antineutrophil Cytoplasmic Antibody–Associated Vasculitis With Eculizumab
por: Huizenga, Noah, et al.
Publicado: (2019)

PReS-FINAL-2311: Rituximab in paediatric ANCA-associated vasculitis
por: Mestrallet, G, et al.
Publicado: (2013)

Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial
por: Smith, Rona M, et al.
Publicado: (2023)

ExploriNg DUrable Remission with Rituximab in ANCA-associatEd vasculitis (ENDURRANCE trial): protocol for a randomised controlled trial
por: Dirikgil, Ebru, et al.
Publicado: (2022)

The Efficacy and Safety of Rituximab in ANCA-Associated Vasculitis: A Systematic Review
por: Habibi, Mohammad Amin, et al.
Publicado: (2022)

Rituximab-associated hypogammaglobulinemia in ANCA-associated vasculitis: Incidence and time course
por: Tariq, Anam, et al.
Publicado: (2022)

Low-dose glucocorticoids plus rituximab versus high-dose glucocorticoids plus rituximab for remission induction in ANCA-associated vasculitis (LoVAS): protocol for a multicentre, open-label, randomised controlled trial
por: Furuta, Shunsuke, et al.
Publicado: (2017)

Membranous Nephropathy with Proteinase 3-ANCA-associated Vasculitis Successfully Treated with Rituximab
por: Yoshida, Shun, et al.
Publicado: (2020)

COVID-19 and ANCA-associated vasculitis: recommendations for vaccine preparedness and the use of rituximab
por: Bruchfeld, Annette, et al.
Publicado: (2021)

Correction: Low-dose glucocorticoids plus rituximab versus high-dose glucocorticoids plus rituximab for remission induction in ANCA-associated vasculitis (LoVAS): protocol for a multicentre, open-label, randomised controlled trial
Publicado: (2018)

Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation
por: Miyazaki, Yusuke, et al.
Publicado: (2020)

Long-term maintenance rituximab for ANCA-associated vasculitis: relapse and infection prediction models
por: McClure, Mark E, et al.
Publicado: (2020)

Complete remission of coronary vasculitis in Churg–Strauss Syndrome by prednisone and cyclophosphamide
por: Riksen, Niels P., et al.
Publicado: (2010)

ANCA Vasculitis Induction Management During the COVID-19 Pandemic
por: Salas, Antonio, et al.
Publicado: (2021)

Kinetics of human leukocyte antigen receptor HLA-DR(+) monocytes and T lymphocytes during remission induction therapy in ANCA-associated vasculitis
por: Tampe, Désirée, et al.
Publicado: (2022)

ANCA associated vasculitis
por: Hunter, Robert W, et al.
Publicado: (2020)

Renal improvement and remission in a patient with refractory ANCA-associated vasculitis treated with avacopan
por: Alvarez, Luis, et al.
Publicado: (2023)

Outcomes of COVID-19 in patients with ANCA-associated vasculitis receiving avacopan
por: Aqeel, Faten, et al.
Publicado: (2023)

Rituximab 500 mg 6-monthly infusions is an option in maintenance therapy of ANCA-associated vasculitis
por: Goel, Ruchika, et al.
Publicado: (2021)

Combination therapy with rituximab and cyclophosphamide in the treatment of anti-neutrophil cytoplasmic antibodies (ANCA) positive pulmonary hemorrhage: case report
por: Baird, Emily M, et al.
Publicado: (2011)

Rituximab vs Cyclophosphamide Induction Therapy for Patients With Granulomatosis With Polyangiitis
por: Puéchal, Xavier, et al.
Publicado: (2022)

Impact of Rituximab on Immunoglobulin Concentrations and B Cell Numbers after Cyclophosphamide Treatment in Patients with ANCA-Associated Vasculitides
por: Venhoff, Nils, et al.
Publicado: (2012)

The immunopathology of ANCA-associated vasculitis
por: McKinney, Eoin F., et al.
Publicado: (2014)

Immunopathogenesis of ANCA-Associated Vasculitis
por: Kronbichler, Andreas, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8qdodqlg0rukq4qo5qaihssolv